NTLA catalyst calendar

Intellia Therapeutics, Inc.

Upcoming catalysts
3
Cash runway
11.2 months
Cash & investments
$438M
Phase 3 programs
3

Intellia Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: In Vitro & In Vivo Diagnostic Substances.

The next scheduled catalyst is Next quarterly earnings (projected) on November 1, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 11.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 1, 2026 est. Next quarterly earnings (projected) Earnings —
July 15, 2027 A Phase 3 Study of NTLA-2001 in ATTRv-PN Trial Milestone Phase 3
December 15, 2027 MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Trial Milestone Phase 3

Track NTLA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NTLA in the tracker

Recent history

DateEventTypePhase
September 8, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 4, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 6, 2026 Quarterly results filed (8-K) Earnings —
June 15, 2026 8-K filed: Reg FD disclosure, Other event Filing —
May 11, 2026 Quarterly results filed (8-K) Earnings —
April 30, 2026 Quarterly results filed (8-K) Earnings —
April 27, 2026 8-K filed: Reg FD disclosure, Other event Filing —
March 2, 2026 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
February 26, 2026 Quarterly results filed (8-K) Earnings —
February 10, 2026 HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Trial Milestone Phase 3
January 27, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 9, 2026 8-K filed: Reg FD disclosure, Other event Filing —
November 10, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
October 29, 2025 8-K filed: Other event Filing —
October 27, 2025 8-K filed: Reg FD disclosure, Other event Filing —
September 25, 2025 8-K filed: Reg FD disclosure, Other event Filing —
September 12, 2025 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) Trial Milestone Phase 1
August 7, 2025 Quarterly results filed (8-K) Earnings —
June 16, 2025 8-K filed: Reg FD disclosure, Other event Filing —
June 12, 2025 8-K filed: Leadership change Corporate —
May 28, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 19, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 4, 2024 NTLA-2002 in Adults With Hereditary Angioedema (HAE) Trial Milestone Phase 1/Phase 2
July 21, 2022 Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.